Rules/misleading presentation/US-MIS-022

Communications should not overstate study findings

AI-verifiedwarningFDA guidance · non-bindingRaised as a question — a person decides

Rule

FDA recommends that communications not overstate the findings of, or the conclusions that can be drawn from, a study or analysis.

Check

Compare the claim's strength of language to what the underlying study can actually support. A violation looks like definitive claims from exploratory, underpowered, or otherwise limited analyses.

Escalate when

Always — requires judgment about whether stated conclusions exceed what the evidence supports.

Where this comes from

Q.6/A.6 · page 15. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…e of their product and from postmarket studies and analyses of their product. As a general matter, FDA believes that a variety of types of studies and analyses can provide useful additional information about a medical product for its approved/cleared conditions of use. However, some of these studies or analyses do not, in and of themselves, allow for reliable conclusions to be drawn about the effects of the product. To be considered truthful and non-misleading, firms’ product communications should not overstate the findings of or the conclusions that can be drawn from such studies or analyses, or fail to disclose their material limitations. For example, certain analyses of pivotal trial data may provide information that elaborates on the data reflected in the product’s FDA-required labeling and could add to understanding of a product (e.g., information from separate analyses of the individual components of a composite endpoint that was successfully used as the primary endpoint and that are derived from appropriate statistical tests and pre-specified i…

Open the original at page 15 on fda.gov ↗Read our full copy →

Document: FDA guidance: Medical Product Communications that Are Consistent With the FDA-Required Labeling – Questions and Answers (final)
Version: as retrieved — the publisher does not version this document; the fingerprint below identifies the exact file
Retrieved: 2026-09-21 from www.fda.gov
Fingerprint: 1a18b7f242bfbbf897f198df…

FDA guidance describes the agency's current thinking. It is not binding law, and this rule is a recommendation, not an obligation.

Applies when

Naturepromotional

Basisconsistent-with-labeling

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-code:sonnet · 2026-09-21
Independent verification — revise
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote is verbatim from the third paragraph of A.6 and the rule statement tracks it faithfully, including keeping the non-binding framing ('FDA recommends ... should not overstate'), so the modality is right for a guidance document that is headed 'Contains Nonbinding Recommendations'.
- The rule bundles two independently checkable requirements: (a) the claim must not overstate the findings/conclusions of the study, and (b) material limitations of that study must be disclosed. The rule's own Check text describes them as two separate operations ('Compare the claim's strength ... and confirm material limitations ... are disclosed'), and a communication can fail either one without failing the other. That is a bundle, not an atomic rule.
- 'judgment' is correct: whether a claim overstates what a study supports, and whether a limitation is 'material', turn on adequacy and impression, not presence/absence.
- 'guidance' is correct — A.6 is FDA recommendation, not statute or regulation. Severity 'warning' is defensible for a recommendation whose breach makes a communication likely misleading.
- applies_when is narrower than the quoted sentence (which says 'firms' product communications') but the surrounding question is expressly 'What evidentiary support should a firm have for its CFL promotional communications?'. Restricting to promotional is therefore justified; however the CFL limit that scopes the whole guidance is not encoded, unlike sibling rule US-SUB-008 drawn from the same answer, which carries basis: consistent-with-labeling.
- Locator Q.6/A.6 is correct.
Revised by the drafter
claude-code:sonnet · 2026-09-21
Independent verification — pass
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote is a complete sentence from Q.6/A.6 and states the recommendation directly; the rule takes only its first limb (do not overstate findings or conclusions), leaving the limitations limb to a separate rule, which is the right split.
- Not overstated: the source's 'should not' is rendered as 'FDA recommends that communications not overstate,' with no conversion of a recommendation into an obligation.
- Atomic: one checkable requirement about the strength of stated findings/conclusions relative to the underlying study or analysis.
- Determinism 'judgment' is correct — whether a claim exceeds what the evidence supports is not settled by presence/absence or a literal match.
- Authority 'guidance' matches the source document and the rule claims no more; it is not a restatement of a statute or regulation quoted by the guidance (the surrounding truthful-and-non-misleading framing is separate). applies_when (promotional, consistent-with-labeling) matches the guidance's own statement that its truthful/non-misleading recommendations apply only to CFL promotional communications, and the Q.6/A.6 locator is right. 'Warning' is defensible for a category that ranges from mild overstatement to serious overclaiming.

Nearby rules

US-MIS-023 US-MIS-024 US-MIS-025 US-MIS-056 US-SUB-008